Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2017 | EBV and MSI – subsets of gastric cancer that respond better to therapy

Ronan Joseph Kelly, MBA, MBBCh, MD, from the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the treatment of gastric and esophageal cancer with pembrolizumab or nivolumab, whereby patients with Epstein-Barr virus or microsatellite instability have been found to respond better to therapy. He states that current research is focused on combining multiple immunotherapeutic agents, with the hope to benefit patients who are PDL1-negative or do not have the aforementioned subsets of cancer. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.